Alembic Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Alembic Pharmaceuticals heeft een totaal eigen vermogen van ₹48.9B en een totale schuld van ₹9.9B, wat de schuld-eigenvermogensverhouding op 20.4% brengt. De totale activa en totale passiva bedragen respectievelijk ₹72.3B en ₹23.4B. De EBIT Alembic Pharmaceuticals is ₹7.2B waardoor de rentedekking 12.9 is. Het heeft contanten en kortetermijnbeleggingen van ₹1.3B.
Belangrijke informatie
20.4%
Verhouding schuld/eigen vermogen
₹9.95b
Schuld
| Rente dekkingsratio | 12.9x |
| Contant | ₹1.29b |
| Aandelen | ₹48.88b |
| Totaal verplichtingen | ₹23.43b |
| Totaal activa | ₹72.30b |
Recente financiële gezondheidsupdates
Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Recent updates
Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts
Nov 10Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price
Sep 25Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 13Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher
Jul 20Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?
May 11Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 08Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%
Jan 21Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Apr 13Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jan 04We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now
Nov 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden
Aug 10Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Jul 20Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( ₹37.6B ) APLLTD } overtreffen de korte termijn passiva ( ₹21.7B ).
Langlopende schulden: De kortetermijnactiva APLLTD ( ₹37.6B ) overtreffen de langetermijnschulden ( ₹1.7B ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: De netto schuld/eigen vermogen ratio ( 17.7% ) APLLTD wordt als voldoende beschouwd.
Schuld verminderen: De schuld/eigen vermogen-ratio van APLLTD is de afgelopen 5 jaar gedaald van 51.8% naar 20.4%.
Schuldendekking: De schuld van APLLTD wordt goed gedekt door de operationele kasstroom ( 41.1% ).
Rentedekking: De rentebetalingen op de schuld van APLLTD worden goed gedekt door EBIT ( 12.9 x dekking).